Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock soar 7.83% in pre-market trading on Monday after the company reported better-than-expected second quarter 2025 financial results. The precision oncology company demonstrated significant improvements in revenue growth and cost control, narrowing its losses substantially compared to the previous year.

Key highlights from the Q2 2025 earnings report include: - Total revenues increased 9.6% year-over-year to RMB148.5 million (US$20.7 million) - Gross profit rose 13.3% to RMB108.1 million (US$15.1 million) - Operating expenses decreased 42.1% to RMB119.6 million (US$16.7 million) - Net loss narrowed to RMB9.7 million (US$1.4 million), compared to RMB108.0 million in Q2 2024

The company's pharma research and development services segment showed particularly strong growth, with revenue increasing 68.1% year-over-year. This growth, combined with effective cost management across all business segments, contributed to the improved financial performance. Investors appear to be responding positively to Burning Rock's progress in reducing losses while maintaining revenue growth, driving the stock's significant uptick in pre-market trading.